\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Corporate Profile

Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Three clinical programs are advancing and demonstrating the safety and efficacy of onvansertib: Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); Phase 2 study of onvansertib in combination with Zytiga® (abirterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML).

Investor Presentation / Company Overview (button) - April 2021
Recent News
Jul 12, 2021

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including...

Jul 6, 2021

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including...

Jun 28, 2021

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including...

More >

Stock Information
NASDAQCRDF
Contact Investor Relations

Direct     [USA +1] 858-952-7593
E-mail    ir@cardiffoncology.com

Contact

Events
July 15, 2021
9:00am - 9:45am PDT

William Blair Biotech Focus Conference Dr. Mark Erlander, chief executive officer of Cardiff Oncology, will participate in a fireside chat at the William Blair Biotech Focus Conference on July 15,...

June 1, 2021
1:00pm - 1:30pm PDT

Dr. Mark Erlander, chief executive officer of Cardiff Oncology, will present and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.

April 12, 2021
8:00am - 9:30am PDT

The webinar will feature presentations by Key Opinion Leaders (KOLs) Daniel H. Ahn, D.O. (Mayo Clinic Arizona) and Manish R. Sharma, M.D. (START Midwest), who will discuss the current treatment...